ClinicalTrials.gg
CompletedNCT06316973Updated Nov 10, 2025Results posted

A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants

A Phase 1 interventional study of CS-1103 and Sterile Saline in Substance Use Disorders, Methamphetamine Abuse and Methamphetamine Intoxication, sponsored by Clear Scientific, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by Clear Scientific, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,589 studies in Substance-Related Disorders with a site in United States — 249 open to participants now, 313 under way, 4 of them phase 3. Substance-Related Disorders · United States.

Enrollment
1,141st of 1,447
32 · median 104
Started
2024
with 73 others
Phase 1
131 of 1,589
14 open now
Registered
1,362nd of 1,589
by date

Among the 1,589 studies in Substance-Related Disorders with a site in United States, this one is the 1,141st largest by enrollment of the 1,447 interventional ones that give a count, is one of 74 that started in 2024, is one of 131 in phase 1, and was the 1,362nd registered.

Substance-Related Disorders

2,241 studies on the registry are indexed under Substance-Related Disorders; 409 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

249 of the 1,589 studies in Substance-Related Disorders with a site in United States are open now. Recruiting first, the newest first:

244 more — sign in →

All 249 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 264 Substance-Related Disorders studies recruiting now, 129 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,589 studies in Substance-Related Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants.

03

Conditions studied

  • Substance Use Disorders
  • Methamphetamine Abuse
  • Methamphetamine Intoxication
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Major Inclusion Criteria:

  1. Healthy male and/or female participants aged 18 to 55 years, inclusive.
  2. A between 18.0 to 30.0 kg/m2, inclusive, and a minimum body weight of 50 kg.
  3. Females must be of nonchildbearing potential.

Major Exclusion Criteria:

  1. Estimated \<90 mL/min/1.73 m2
  2. Any abnormalities in rhythm, conduction or morphology of the resting , and any clinically important abnormalities in the 12-lead ECG
  3. Current smokers, or those who have smoked or used nicotine products (including nicotine patches) within 1 month prior to dose administration.
  4. History of alcohol abuse or excessive intake of alcohol
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Cohort 1

    6 participants received a single dose of 2.7 mg/kg (2.5 mg/kg free acid) CS-1103 administered as solution for infusion by IV over 10 minutes. A diluted CS-1103 saline solution in an IV bag is used for drug administration.

    Drug: CS-1103

  • Experimental
    Cohort 2

    6 participants received single dose of 8.0 mg/kg (7.5 mg/kg free acid) CS-1103 administered as solution for infusion by IV over 10 minutes. A diluted CS-1103 saline solution in an IV bag is used for drug administration.

    Drug: CS-1103

  • Experimental
    Cohort 3

    6 participants received a single dose of 16.0 mg/kg (15.1 mg/kg free acid) CS-1103 administered as solution for infusion by IV over 10 minutes. A diluted CS-1103 saline solution in an IV bag is used for drug administration.

    Drug: CS-1103

  • Experimental
    Cohort 4

    6 participants received a single dose of 19.0 mg/kg (17.9 mg/kg free acid) CS-1103 administered as solution for infusion by IV over 10 minutes. A diluted CS-1103 saline solution in an IV bag is used for drug administration.

    Drug: CS-1103

  • Placebo comparator
    Placebo

    2 participants for each cohort were administered with placebo. Total administered volume of saline matched administered volume for the corresponding CS-1103 solution in each cohort.

    Drug: Sterile Saline

Interventions

  • CS-1103 for infusion

  • DrugSterile Saline

    Sterile Saline for Injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs)

    Treatment-emergent adverse events assessed through physical examinations, vital signs (blood pressure, pulse rate, respiratory rate, oxygen saturation, and body temperature), electrocardiograms (digital 12-lead electrocardiograms (ECGs). Any correlation between CS-1103 plasma concentrations and changes in QT intervals will be noted), and laboratory parameters (clinical chemistry, hematology, coagulation, and urinalysis).

    Time frame: 3 days plus 8 days for follow-up

  2. Number of Participants by Severity of AEs

    Severity of AEs was classified as mild, moderate, or severe (increasing severity). A subject experiencing multiple occurrences of an adverse event in a particular category was counted, at most, once for that category for each treatment.

    Time frame: 3 days plus 8 days for follow-up

Secondary outcomes

  1. Plasma Pharmacokinetic (PK) Parameter: Cmax

    Maximum concentration, obtained directly from the observed concentration versus time data.

    Time frame: End-of-Infusion (EOI), 5, 10, 20, 30, 40 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 hr

  2. Plasma PK Parameter: Tmax

    Time of maximum observed blood plasma concentration (Cmax) of CS-1103

    Time frame: End-of-Infusion (EOI), 5, 10, 20, 30, 40 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 hr

  3. Plasma PK Parameter: t1/2

    Terminal Elimination Half-life of CS-1103

    Time frame: End-of-Infusion (EOI), 5, 10, 20, 30, 40 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 hr

  4. Plasma PK Parameter: CL

    Systemic Clearance of CS-1103

    Time frame: End-of-Infusion (EOI), 5, 10, 20, 30, 40 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 hr

  5. Plasma PK Parameter: Vz

    Volume of Distribution of CS-1103

    Time frame: End-of-Infusion (EOI), 5, 10, 20, 30, 40 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 hr

  6. Urine PK Parameter: Fe (0-last)

    Cumulative fraction of dose excreted in urine during the pooled collection intervals. Due to inherent error in measuring CS-1103 recovered in urine, the calculated recovery may exceed 100% of the dose.

    Time frame: Time intervals from 0-24 hours after IV administration of CS-1103

07

Results

Posted Nov 10, 2025

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 (2.5 mg/kg CS-1103 [Free Acid])Cohort 2 (7.5 mg/kg CS-1103 [Free Acid])Cohort 3 (15.1 mg/kg CS-1103 [Free Acid])Cohort 4 (17.9 mg/kg CS-1103 [Free Acid])Placebo
Started66668
Completed66668
Not completed00000

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (AEs)

Treatment-emergent adverse events assessed through physical examinations, vital signs (blood pressure, pulse rate, respiratory rate, oxygen saturation, and body temperature), electrocardiograms (digital 12-lead electrocardiograms (ECGs). Any correlation between CS-1103 plasma concentrations and changes in QT intervals will be noted), and laboratory parameters (clinical chemistry, hematology, coagulation, and urinalysis).

Time frame:
3 days plus 8 days for follow-up
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs)
ParticipantsCohort 1 (2.5 mg/kg CS-1103 [Free Acid])Cohort 2 (7.5 mg/kg CS-1103 [Free Acid])Cohort 3 (15.1 mg/kg CS-1103 [Free Acid])Cohort 4 (17.9 mg/kg CS-1103 [Free Acid])Placebo
TEAEs11240
Related TEAEs00140
Serious TEAEs00000
TEAEs leading to study discontinuation00000
TEAEs leading to death00000
PrimaryNumber of Participants by Severity of AEs

Severity of AEs was classified as mild, moderate, or severe (increasing severity). A subject experiencing multiple occurrences of an adverse event in a particular category was counted, at most, once for that category for each treatment.

Time frame:
3 days plus 8 days for follow-up
Reported as:
Count of participants · Participants
Number of Participants by Severity of AEs
ParticipantsCohort 1 (2.5 mg/kg CS-1103 [Free Acid])Cohort 2 (7.5 mg/kg CS-1103 [Free Acid])Cohort 3 (15.1 mg/kg CS-1103 [Free Acid])Cohort 4 (17.9 mg/kg CS-1103 [Free Acid])Placebo
Mild11240
Moderate00000
Severe00000
SecondaryPlasma Pharmacokinetic (PK) Parameter: Cmax

Maximum concentration, obtained directly from the observed concentration versus time data.

Time frame:
End-of-Infusion (EOI), 5, 10, 20, 30, 40 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 hr
Reported as:
Geometric mean · μg/mL
Plasma Pharmacokinetic (PK) Parameter: Cmax
μg/mLCohort 1 (2.5 mg/kg CS-1103 [Free Acid])Cohort 2 (7.5 mg/kg CS-1103 [Free Acid])Cohort 3 (15.1 mg/kg CS-1103 [Free Acid])Cohort 4 (17.9 mg/kg CS-1103 [Free Acid])
Plasma Pharmacokinetic (PK) Parameter: Cmax20.78 ± 31.358.25 ± 17.7156.9 ± 24.8176.0 ± 17.9
SecondaryPlasma PK Parameter: Tmax

Time of maximum observed blood plasma concentration (Cmax) of CS-1103

Time frame:
End-of-Infusion (EOI), 5, 10, 20, 30, 40 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 hr
Reported as:
Median · hours
Plasma PK Parameter: Tmax
hoursCohort 1 (2.5 mg/kg CS-1103 [Free Acid])Cohort 2 (7.5 mg/kg CS-1103 [Free Acid])Cohort 3 (15.1 mg/kg CS-1103 [Free Acid])Cohort 4 (17.9 mg/kg CS-1103 [Free Acid])
Plasma PK Parameter: Tmax0.235 (0.180 to 0.270)0.180 (0.180 to 0.330)0.180 (0.180 to 0.330)0.180 (0.180 to 0.250)
SecondaryPlasma PK Parameter: t1/2

Terminal Elimination Half-life of CS-1103

Time frame:
End-of-Infusion (EOI), 5, 10, 20, 30, 40 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 hr
Reported as:
Geometric mean · hours
Plasma PK Parameter: t1/2
hoursCohort 1 (2.5 mg/kg CS-1103 [Free Acid])Cohort 2 (7.5 mg/kg CS-1103 [Free Acid])Cohort 3 (15.1 mg/kg CS-1103 [Free Acid])Cohort 4 (17.9 mg/kg CS-1103 [Free Acid])
Plasma PK Parameter: t1/24.323 ± 26.44.118 ± 13.74.215 ± 17.44.558 ± 19.9
SecondaryPlasma PK Parameter: CL

Systemic Clearance of CS-1103

Time frame:
End-of-Infusion (EOI), 5, 10, 20, 30, 40 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 hr
Reported as:
Geometric mean · L/h
Plasma PK Parameter: CL
L/hCohort 1 (2.5 mg/kg CS-1103 [Free Acid])Cohort 2 (7.5 mg/kg CS-1103 [Free Acid])Cohort 3 (15.1 mg/kg CS-1103 [Free Acid])Cohort 4 (17.9 mg/kg CS-1103 [Free Acid])
Plasma PK Parameter: CL0.04915 ± 24.20.04971 ± 16.10.04762 ± 20.60.05040 ± 17.3
SecondaryPlasma PK Parameter: Vz

Volume of Distribution of CS-1103

Time frame:
End-of-Infusion (EOI), 5, 10, 20, 30, 40 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 hr
Reported as:
Geometric mean · L
Plasma PK Parameter: Vz
LCohort 1 (2.5 mg/kg CS-1103 [Free Acid])Cohort 2 (7.5 mg/kg CS-1103 [Free Acid])Cohort 3 (15.1 mg/kg CS-1103 [Free Acid])Cohort 4 (17.9 mg/kg CS-1103 [Free Acid])
Plasma PK Parameter: Vz0.3065 ± 15.00.2953 ± 7.80.2896 ± 12.00.3273 ± 24.0
SecondaryUrine PK Parameter: Fe (0-last)

Cumulative fraction of dose excreted in urine during the pooled collection intervals. Due to inherent error in measuring CS-1103 recovered in urine, the calculated recovery may exceed 100% of the dose.

Time frame:
Time intervals from 0-24 hours after IV administration of CS-1103
Reported as:
Mean · percentage of dose administered
Urine PK Parameter: Fe (0-last)
percentage of dose administeredCohort 1 (2.5 mg/kg CS-1103 [Free Acid])Cohort 2 (7.5 mg/kg CS-1103 [Free Acid])Cohort 3 (15.1 mg/kg CS-1103 [Free Acid])Cohort 4 (17.9 mg/kg CS-1103 [Free Acid])
Urine PK Parameter: Fe (0-last)91.58 ± 12.37108.3 ± 4.227101.0 ± 5.43398.70 ± 9.129

Adverse events

Collected over 3 days plus 8 days for follow-up. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 (2.5 mg/kg CS-1103 [Free Acid])0/6 (0%)0/6 (0%)1/6 (16.7%)
Cohort 2 (7.5 mg/kg CS-1103 [Free Acid])0/6 (0%)0/6 (0%)1/6 (16.7%)
Cohort 3 (15.1 mg/kg CS-1103 [Free Acid])0/6 (0%)0/6 (0%)2/6 (33.3%)
Cohort 4 (17.9 mg/kg CS-1103 [Free Acid])0/6 (0%)0/6 (0%)4/6 (66.7%)
Placebo0/8 (0%)0/8 (0%)0/8 (0%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventCohort 1 (2.5 mg/kg CS-1103 [Free Acid])Cohort 2 (7.5 mg/kg CS-1103 [Free Acid])Cohort 3 (15.1 mg/kg CS-1103 [Free Acid])Cohort 4 (17.9 mg/kg CS-1103 [Free Acid])Placebo
Eustachian tube dysfunctionEar and labyrinth disorders0/60/61/62/60/8
SneezingRespiratory, thoracic and mediastinal disorders0/60/60/62/60/8
PalpitationsCardiac disorders1/60/60/60/60/8
TachycardiaCardiac disorders0/60/61/60/60/8
TinnitusEar and labyrinth disorders0/60/60/61/60/8
Periorbital oedemaEye disorders0/60/61/60/60/8
Abdominal painGastrointestinal disorders1/60/60/60/60/8
Gingival painGastrointestinal disorders0/60/60/61/60/8
NauseaGastrointestinal disorders0/60/60/61/60/8
Skin abrasionInjury, poisoning and procedural complications1/60/60/60/60/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1 (2.5 mg/kg CS-1103 [Free Acid])Cohort 2 (7.5 mg/kg CS-1103 [Free Acid])Cohort 3 (15.1 mg/kg CS-1103 [Free Acid])Cohort 4 (17.9 mg/kg CS-1103 [Free Acid])PlaceboTotal
Mean29.7 ± 10.730.3 ± 8.339.5 ± 9.038.5 ± 7.936.3 ± 10.434.9 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (2.5 mg/kg CS-1103 [Free Acid])Cohort 2 (7.5 mg/kg CS-1103 [Free Acid])Cohort 3 (15.1 mg/kg CS-1103 [Free Acid])Cohort 4 (17.9 mg/kg CS-1103 [Free Acid])PlaceboTotal
Female013004
Male6536828
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 (2.5 mg/kg CS-1103 [Free Acid])Cohort 2 (7.5 mg/kg CS-1103 [Free Acid])Cohort 3 (15.1 mg/kg CS-1103 [Free Acid])Cohort 4 (17.9 mg/kg CS-1103 [Free Acid])PlaceboTotal
Hispanic or Latino020204
Not Hispanic or Latino6464828
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 (2.5 mg/kg CS-1103 [Free Acid])Cohort 2 (7.5 mg/kg CS-1103 [Free Acid])Cohort 3 (15.1 mg/kg CS-1103 [Free Acid])Cohort 4 (17.9 mg/kg CS-1103 [Free Acid])PlaceboTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American1452618
White4214213
More than one race100001
Unknown or Not Reported000000
BMI
BMI(kg/m^2)Cohort 1 (2.5 mg/kg CS-1103 [Free Acid])Cohort 2 (7.5 mg/kg CS-1103 [Free Acid])Cohort 3 (15.1 mg/kg CS-1103 [Free Acid])Cohort 4 (17.9 mg/kg CS-1103 [Free Acid])PlaceboTotal
Mean25.815 ± 2.47924.728 ± 3.45124.528 ± 2.73125.975 ± 2.60226.161 ± 2.30825.487 ± 2.624
Weight
Weight(kg)Cohort 1 (2.5 mg/kg CS-1103 [Free Acid])Cohort 2 (7.5 mg/kg CS-1103 [Free Acid])Cohort 3 (15.1 mg/kg CS-1103 [Free Acid])Cohort 4 (17.9 mg/kg CS-1103 [Free Acid])PlaceboTotal
Mean83.30 ± 11.8172.97 ± 8.3068.32 ± 6.9376.20 ± 9.2779.44 ± 6.7776.26 ± 9.60
Height
Height(cm)Cohort 1 (2.5 mg/kg CS-1103 [Free Acid])Cohort 2 (7.5 mg/kg CS-1103 [Free Acid])Cohort 3 (15.1 mg/kg CS-1103 [Free Acid])Cohort 4 (17.9 mg/kg CS-1103 [Free Acid])PlaceboTotal
Mean179.23 ± 6.59170.80 ± 10.11166.97 ± 6.65171.12 ± 5.98174.63 ± 5.42172.68 ± 7.73
08

Study locations

1 site
  • Dr. Vince Clinical Research
    Overland Park, Kansas 66212, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in May 2024, 3 months.

Results were first posted in Nov 2025, 1 year 5 months after primary completion.

Of 24 industry-sponsored phase 1 interventional studies under Substance-Related Disorders, half reached primary completion within 4 months of starting (the median); a quarter within 3 and three quarters within 9. This study's 3 months is below that.

Counting every sponsor, half of 54 studies reached it within 12 months; a quarter within 4 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2024
First posted
Mar 19, 2024
StartActual
Feb 7, 2024
Primary completionActual
May 30, 2024
CompletionActual
Jun 6, 2024
Results first posted
Nov 10, 2025
Last update
Nov 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06316973
Lead sponsor
Clear Scientific, Inc.
Responsible party
Sponsor
First posted
Mar 19, 2024
Start date
Feb 7, 2024
Primary completion
May 30, 2024
Completion
Jun 6, 2024
Results posted
Nov 10, 2025
Last update
Nov 10, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CS-1103

Start the discussion